Leflunomide for the Treatment of Rheumatoid Arthritis and Autoimmunity

  title={Leflunomide for the Treatment of Rheumatoid Arthritis and Autoimmunity},
  author={S Sanders and Valee Harisdangkul},
  journal={The American Journal of the Medical Sciences},
&NA; Leflunomide, a new oral immunomodulatory agent, is effective for the treatment of rheumatoid arthritis. Its mechanism of action in suppressing inflammation is based in its inhibition of dihydroorotate dehydrogenase, an enzyme responsible for de novo synthesis of pyrimidine containing ribonucleotides. It is the first disease‐modifying antirheumatic drug approved for treatment of rheumatoid arthritis with an indication for retardation of joint damage by radiography. Side effects are… 

Effects of leflunomide on human cartilage.

Leflunomide Treatment in Elderly Patients with Rheumatoid or Psoriatic Arthritis

The safety profile of, and adherence to, leflunomide is not different in older patients with chronic inflammatory joint diseases such as RA or psoriatic arthritis to that observed in younger patients, and the types of adverse effects associated with monotherapy or combination therapy when the two age groups were compared.

From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis

Teriflunomide has shown a favorable safety and efficacy profile in RRMS and is a therapeutic option for a distinct group of adult patients with RRMS.

Treatment of primary Sjögren syndrome

The available data on topical and systemic medications, according to clinical signs and disease activity, is summarized, and the ongoing studies using biologic drugs in the treatment of pSS are described.

Efficacy and tolerability of leflunomide in difficult‐to‐treat polymyalgia rheumatica and giant cell arteritis: a case series

Leflunomide is efficacious, with 22 out of 23 patients exhibiting a complete or partial response and it was also steroid sparing and well tolerated, suggesting it may be a useful adjunctive agent in difficult‐to‐treat GCA and PMR.

Arava Treatment, between Beneficial Action on Joint Inflammation and Side Effects on Liver, Myocardium and Kidney in Experimental Murine Arthritis

The experiment revealed the toxic visceral effects of Leflunomide on the liver, heart and kidney and improved the course of the clinical and paraclinical parameters, but it did not cure the condition.



Mechanism of action for leflunomide in rheumatoid arthritis.

It is proposed that leflunomide prevents the expansion of activated and autoimmune lymphocytes by interfering with the cell cycle progression due to inadequate production of rUMP and utilizing mechanisms involving p53.

Severe pancytopenia after leflunomide in rheumatoid arthritis.

A 62-year-old woman with a 14-year history of rheumatoid arthritis with bone marrow toxicity and reversible pancytopenia developing after treatment with leflunomide is reported.

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.

Clinical responses following administration of leflunomide, a new therapeutic agent for the treatment of RA, were statistically superior to those with placebo and equivalent to Those with methotrexate treatment.

Treatment of Felty's syndrome with leflunomide.

A case of severe FS that developed in a patient receiving methotrexate therapy for RA and responded to treatment with leflunomide, which included dramatic improvement of leukopenia and neutropenia as well as excellent control of his arthritis.

Mechanism of action of leflunomide in rheumatoid arthritis.

  • R. Fox
  • Biology, Medicine
    The Journal of rheumatology. Supplement
  • 1998
In support of this mechanism of action, in vitro mitogen stimulated human peripheral blood lymphocytes treated with A77 1726 undergo arrest at the G1 phase; this inhibition is reversed by uridine.

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.

The combination of methotrexate and leflunomide has therapeutic potential in RA and was generally well tolerated clinically, with the exception of elevations of liver enzyme levels.

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

Both leflunomide and methotrexate are efficacious for prolonged treatment of RA and this benefit must be weighed against the potential toxicity of this drug when used without folate supplementation.

New concepts in treatment protocols for severe systemic vasculitis.

  • W. Gross
  • Medicine, Biology
    Current opinion in rheumatology
  • 1999
Pulse cyclophosphamide has been shown to be as effective as the standard therapy in necrotizing vasculitides; however, an alarmingly high rate of infections was observed in this study in both arms possibly related to the high dosage of GCs.

Rational Use of New and Existing Disease-Modifying Agents in Rheumatoid Arthritis

  • J. Kremer
  • Medicine
    Annals of Internal Medicine
  • 2001
After a period of more than a decade in which virtually no new DMARDs to treat patients with rheumatoid arthritis were introduced, the present environment represents an unprecedented and extraordinary expansion of therapeutic possibilities from which to choose.